Analytical Data
-
Gene name
B3GALTL
- Application
-
Alternative Names
B3GLCT; B3GALTL; B3GTLBeta-1.3-glucosyltransferase; Beta3Glc-T; EC 2.4.1
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q6Y288
-
Expression Region
21-498aa
-
AA Sequence
MRPPACWWLLAPPALLALLTCSLAFGLASEDTKKEVKQSQDLEKSGISRKNDIDLKGIVFVIQSQSNSFHAKRAEQLKKSILKQAADLTQELPSVLLLHQLAKQEGAWTILPLLPHFSVTYSRNSSWIFFCEEETRIQIPKLLETLRRYDPSKEWFLGKALHDEEATIIHHYAFSENPTVFKYPDFAAGWALSIPLVNKLTKRLKSESLKSDFTIDLKHEIALYIWDKGGGPPLTPVPEFCTNDVDFYCATTFHSFLPLCRKPVKKKDIFVAVKTCKKFHGDRIPIVKQTWESQASLIEYYSDYTENSIPTVDLGIPNTDRGHCGKTFAILERFLNRSQDKTAWLVIVDDDTLISISRLQHLLSCYDSGKPVFLGERYGYGLGTGGYSYITGGGGMVFSREAVRRLLASKCRCYSNDAPDDMVLGMCFSGLGIPVTHSPLFHQARPVDYPKDYLSHQVPISFHKHWNIDPVKVYFTWLAPSDEDKARQETQKGFREEL
-
Molecular Weight
83 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
B3GALTL, or Beta-1,3-galactosyltransferase-like protein, is a crucial enzyme involved in the biosynthesis of glycoproteins and glycolipids, primarily through the transfer of galactose residues. Studies have shown that B3GALTL plays a significant role in various biological processes, including cell adhesion, immune response, and developmental pathways. Deficiencies or mutations in the B3GALTL gene have been linked to several congenital disorders, particularly those affecting brain and nerve development. Given its pivotal role in glycosylation pathways, researchers have been increasingly interested in B3GALTL as a potential biomarker for certain diseases and as a target for therapeutic interventions. The recombinant expression of B3GALTL in various systems allows for the detailed study of its enzymatic characteristics and substrate specificity, facilitating a better understanding of its biological functions. Additionally, characterizing the protein can provide insights into its potential roles in disease mechanisms, paving the way for innovative treatments based on glycoengineering. With advancements in biotechnology, the production of recombinant B3GALTL not only supports fundamental research but also offers practical applications in drug development and personalized medicine.
